Proudly Supported by the Layton Vision Foundation
2026 Optometry Educational Dinner (April)
Wade Core Function Centre (Carina Leagues Club) (Carina , QLD)
Wednesday, 22 April 2026 6:30 pm
TOPIC: Uveitis - Recognition, Referral & Co-management. A 2026 Update.
This clinical presentation provides optometrists with an evidence-based update on uveitis diagnosis, classification and management. Content includes anatomical classification; red flags for same-day referral; topical and systemic pharmacological management; emerging drug-induced uveitis patterns (GLP-1 receptor agonists, checkpoint inhibitors, bisphosphonates); and a practical co-management framework.
Our Presenter – Professor Christopher Layton:
Professor Christopher Layton (Dr Chris) is a private Clinical Ophthalmologist, Rhodes Scholar and a national leader in innovative ophthalmology. His expertise is in macular disease, lens surgery and minimally invasive glaucoma interventions. He completed optometry at QUT, ophthalmology in Queensland, Oxford and London, subspecialty training in retinal disease at the Royal Brisbane Hospital and holds a PhD in diabetic retinopathy from Oxford University. Professor Layton is the founding director of the LVF Ophthalmology Research Centre. He is also CEO of Ocugene, a Queensland based biotech start-up which is commercialising his gene therapy technology targeting macular degeneration, uveitis and choroidal melanoma.
This clinical presentation provides optometrists with an evidence-based update on uveitis diagnosis, classification and management. Content includes anatomical classification; red flags for same-day referral; topical and systemic pharmacological management; emerging drug-induced uveitis patterns (GLP-1 receptor agonists, checkpoint inhibitors, bisphosphonates); and a practical co-management framework.
Our Presenter – Professor Christopher Layton:
Professor Christopher Layton (Dr Chris) is a private Clinical Ophthalmologist, Rhodes Scholar and a national leader in innovative ophthalmology. His expertise is in macular disease, lens surgery and minimally invasive glaucoma interventions. He completed optometry at QUT, ophthalmology in Queensland, Oxford and London, subspecialty training in retinal disease at the Royal Brisbane Hospital and holds a PhD in diabetic retinopathy from Oxford University. Professor Layton is the founding director of the LVF Ophthalmology Research Centre. He is also CEO of Ocugene, a Queensland based biotech start-up which is commercialising his gene therapy technology targeting macular degeneration, uveitis and choroidal melanoma.